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In vitro models of fibrotic phenomena are often based on the fibroblast-myofibroblast transition as the
contraction-triggering cellular event. There are, however, multiple sources of concern regarding the
appropriateness of such models; a first and widely investigated issue is the often inappropriate nature of the
interactions between mesenchymal cells and surrounding/underlying matrix/substrate. A second set of
problems concerns the composition of the fluid phase, which includes both dispersed/dissolved paracrine
messengers and matrix elements. In this study, we have focused on the effects that serum may generate. We
have observed that A) serum causes high variability in the expression of typical markers of myofibroblast
differentiation (ED-A fibronectin and a-Smooth Muscle Actin) upon treatment with TGF-b1; this is
probably due to intrinsic variability of cytokine concentrations in different batches of serum. B) the
fibrillization of endogenous fibronectin is partially hampered and its localization changed from ventral (on
the substrate) to dorsal (upper surface); the latter morphology appears to be largely overlooked in literature,
even though it may have a significant role in terms of mechanotransductive signaling. This quite dramatic
change possibly occurs as a result of competition with serum proteins, although our data seem to rule out a
direct role of serum fibronectin.
M
yofibroblasts, a contractile phenotype of mesenchymal cells, are major players in the contraction phe-
nomena that underpin both physiological wound healing and abnormal scarring, as well as a vast
number of pathological fibrotic/foreign-body reactions1. The availability of appropriate in vitro models
is a major goal in order to understand and control the mechanical and biochemical interactions of myofibroblasts
with the environment surrounding them, and it is a fundamental step towards the development of new therapies.
Mechanotransduction and matrix remodelling specifically play a key and inter-dependent role; for example,
mechanical effects such as the stiffening of the extracellular matrix (ECM) can upregulate the fibroblast proteo-
lytic activity2. In turn, matrix remodeling by enzymes such as Matrix MetalloProteinases (MMPs) can alter the
balance of mechanical forces, with a knock-on effect on the organization of cell cytoskeleton3. However, the
organization of mechanotransductive elements and MMPs in in vitro models has been relatively little studied.
The extracellular fibrillar network formed by fibronectin is one the most critical mechanotransductive com-
ponents4, thanks to its physical continuity with actin fibres via transmembrane integrin association5. Indeed a
distinctive splice variant of fibronectin, the ExtraDomain-A fibronectin (ED-A FN), is critical for acquisition of
the myofibroblast phenotype6; ED-A FN is also commonly used as an early stage marker of this differentiation.
Literature also suggests some links between MMP expression and development of the myofibroblast pheno-
type, and most evidence seems to link MMP-2 (see Supplementary Information, Section 1, Table S1) and MMP-
14 to contraction/fibrotic processes. MMP-2 expression appears to increase in hypertrophic and keloid scars7,8
and in fibrotic liver9,10, and seems to be more associated to the degradation of normal ECM (relatively richer in
collagen IV) rather than that of a more fibrotic one (richer in collagen I)11. MMP-3 may also have a positive
association with myofibroblasts: MMP-3 knockout decreases collagen gel contraction in primary mouse fibro-
blasts in vitro, impairs wound contraction in an in vivo mouse model12, and it has also been shown to induce
Epithelial-Mesenchymal Transition (EMT)13. To our knowledge, limited data exist to support a link with MMP-1,
although an all-in-all negative association may be possible: for example, Transforming Growth Factor b1 (TGF-
b1) treatment decreases MMP-1 expression in keloid fibroblasts, where the reverse occurs upon TGF-b1 inhibi-
tion14. Increased MMP-1 and reduced collagen levels are also associated to an improved wound healing caused by
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basic fibroblast growth factor (bFGF)15. Finally, MMP-1 levels
increase when Smad interacting protein 1 (SIP1) is overexpressed,
which is in turn repressed by TGF-b1 in both normal and patho-
logical scar fibroblasts16.
However, the variability of the in vitro experimental data is a
major issue and frustrates efforts to reach solid conclusions: for
example, most reports show MMP-2 upregulation by TGF-b1, but
some claim downregulation17,18. Similar considerations can be
made also for the quantification of classical markers of the
TGF-b1-induced myofibroblast transition; for example, in a sem-
inal paper on myofibroblast differentiation Gabbiani reported that
the same TGF-b1 concentration induced higher a-Smooth Muscle
Actin (a-SMA) levels with decreasing serum concentration (FBS
or WBS)19. Therefore, it seems reasonable to question whether
in vitro models exist that allow a reproducible myofibroblast gen-
eration and a recapitulation of their in vivo behavior. Firstly, most
models lack a biological or at least biomimetic ECM; this is a key
point, since in vivo a general MMP inhibition causes delayed
myofibroblast differentiation, while this effect is absent on TGF-
b1-treated fibroblast cultures20. Secondly, most data are gathered
from cells cultured on plastics and exposed to TGF-b1, but there
is no general consensus about the necessity of the presence of
serum in the medium, nor about its concentration. Clearly,
serum-free conditions provide an extremely artificial environment
Figure 1 | Expression of (proto)myofibroblastic markers EDA-FN and a-SMA in response to TGF-b1. (A): HDFs showed significant amounts of ED-A
FN already before TGF-b1 treatment, which is a sign of a protomyofibroblastic phenotype. TGF-b1 clearly induced the development of a-SMA in these
cells. (B): Vinculin staining showed that TGF-b1 treatment not only induced the formation of a-SMA-containing stress fibres (green) in HDFs, but also of
focal adhesions at their termini (red, magnified in the circles). (C): Top: TGF- b1 concentration in media containing FBS from different sources, which are
anonimized; please note that supplier A was used for the experiments in panels A and B and for all experiments reported in the rest of the paper. Bottom:
The exposure of HDFs to a 10 ng/mL TGF-b1 dose caused different upregulation of myofibroblast markers depending on the actual TGF-b1 content in
the culture medium (measured via ELISA). n 5 3 for all experiments (two stars: p-value , 0.01, three stars: p-value , 0.001, obtained through a two-
tailed, unpaired T-test).
www.nature.com/scientificreports
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that can hardly mimic the (signalling) complexity of a biological
fluid. On the other hand, the high variability of components pre-
sent in serum may significantly influence myofibroblast differenti-
ation and behavior.
Here, we have investigated the effect of a serum-containing med-
ium (10% FBS) on the expression of markers of myofibroblast dif-
ferentiation and on the (co)localization of structural elements (actin,
fibronectin) and of MMPs.
Results
Influence of serum on myofibroblast markers. Due to their
consistent TGF-b1-induced overexpression of both the protomyo-
fibroblast marker ED-A FN and the myofibroblast marker a-SMA
(Figure 1A), human dermal fibroblasts (HDF) were selected as the
cellular model for this study.
Please see Supplementary Information, section 1, Figure S1, for a
comparison of HDFs with two other common fibroblastic cell types
Figure 2 | FN staining on HDFs. ‘‘General’’ FN was stained via FN-15 antibody (A and B) and ED-A FN via IST-9 (C and D, 10 ng/mL TGF-b1), and both
exhibited a fibrillar organization without serum (A and C), and a predominantly non-fibrillar one under 10% FBS. Oval insets show magnified views of
the interconnection between fibronectin (red) and actin (green) in the absence of serum, while they appear mutually exclusive in its presence. Panels E and
F represent the images in A and D in inverted colours (cyan for FN, magenta for actin) for a clearer appreciation of spatial relation of fibronectin with
actin. Panels G to I summarize the different morphology of endogenous FN with serum (spotted, G) or without serum (fibrillar, H) and actin (fibrillar but
with a different pattern); images G to I were obtained by first inverting the colours of DAPI1actin/FN-stained cells and then converting them to grayscale.
www.nature.com/scientificreports
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(L929 and 3T3 murine cell lines). However, the use of HDFs carries
two important caveats: A) HDFs are already in a protomyofibroblas-
tic (ED-A FN positive) state before TGF-b1 treatment, possibly due
to the stiffness of the plastic substrate. B) the TGF-b1 –stimulated
emergence of myofibroblast markers in serum-containing media was
very variable, with overexpression levels ranging from 2- to 8-fold.
We related the variations in the marker expression to differences in
the supplier and probably in the batch of serum. Indeed, ELISA
analysis showed that sera from different suppliers contained a highly
variable amount of TGF-b1 (up to 1 ng/mL), which appeared to have
an inverse correlation with the marker expression (Figure 1C).
Possibly, the variable TGF-b1 level in commercial sera is one of
the sources of the variability observed in Table S1.
It is worth mentioning that the most reproducible upregulation of
both markers was obtained using a serum-containing medium only
to favour cell attachment, and then performing the TGF-b1 treat-
ment under serum-free conditions.
Influence of serum on the morphology of structural elements.
Both F-actin in untreated fibroblasts, and a-SMA in TGF-b1-treated
ones showed no apparent morphological difference in the presence or
absence of serum (see Figure 2 for an example of F-actin in both
conditions). On the other hand, serum strongly affected the spatial
organization of fibronectin (FN), both in a ‘‘general’’ form (hereafter
referred to simply as FN) and in its ED-A variant, as respectively stained
with the FN-15 and IST-9 monoclonal antibodies (Figure 2). Both with
and without TGF-b1 treatment, FN and ED-A FN predominantly
adopted a fibrillar organization in the absence of serum, and a non-
fibrillar, spot-like morphology in 10% FBS. Note that this does not
necessarily imply the complete absence of fibrils in serum-containing
media (Figure 3), nor the absence of ‘spots’ in a serum-free environ-
ment: HDFs always showed both FN morphologies, although in diffe-
rent relative amounts depending on the culture conditions. Elongated
structures were often seen, which may relate to a transition from ‘‘spots’’
to fibrils; these structures generally appear co-aligned but not over-
lapping with along actin fibres (see e.g. insert in Figure 2D). It is also
noteworthy that FN topology was indistinguishable after 2, 3 and 5 days
of culture in the absence of serum (see Supplementary Information,
Figure S2), therefore indicating a 2-day starvation is sufficient to induce
the morphological difference.
In terms of localization, in serum the non-fibrillar form of FN
appeared to be predominantly present on the upper (dorsal) surface.
For example, it was more visible in widefield than in TIRF images
(Figure 4, top). Since actin appears to be negatively colocalized with
FN/ED-A FN (5mutual exclusion; see e.g. Figure 2F or Figure 4), we
assume the FN ‘‘spots’’ to be located in the grooves between stress
fibres on the upper cell surface (Figure 4, bottom), which would
explain their alignment directed along that of the actin fibres (see
e.g. Figure 2F). The non-fibrillar FN was localized dorsally also under
serum-free conditions, as confirmed also by confocal analysis,
whereas the more common fibrillar form localized ventrally at the
cell/substrate interface (Figure 5).
In the absence of cells, FN morphology depends on the character-
istics of the materials it can bind to 21–23; when in contact with cells,
the major determinant of FN fibrillization is its association to integ-
rins24. This applies to all forms of cellular FN, including ED-A FN: for
example, a largely non-fibrillar ED-A FN was recorded in lymphatic
vessels of mice lacking a9 integrin25. It could be hypothesized that the
reduced FN fibrillization observed in serum may be caused by integ-
rins adhering to the substrate through interactions with competing
molecules from the medium: for example, 20 nM FN in the medium
is sufficient to provide a fibrillar mesh for FN-null fibroblasts26. We
have therefore supplemented the serum-free medium with up to
57 nM bovine FN, but this caused no apparent alteration to the
fibrillar staining pattern of FN15 nor the presence of non-fibrillar
human FN; this would suggest that serum components other than
Figure 3 | Morphology of endogenous ED-A FN for HDFs cultured in a serum-containing medium. The shape is predominantly irregular and
featureless; however, independently on the treatment with TGF-b1, areas of partial fibrillization are often recognizable in up to 30–40% of the cells in any
given population. The insets show magnified views of these areas In particular the images on the left could be consistent with a pre-fibrillar organization
from aligned ‘‘spots’’; however, we are inclined not to follow this hypothesis, due to the dorsal/ventral differential localization of respectively non-fibrillar
and fibrillar FN (see Figure 4).
www.nature.com/scientificreports
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FN may lead the adhesion the cause of the lack of fibrillization (see
Supplementary Information, Figure S5).
The ED-A FN (IST-9 positive) and ‘‘total’’ FN (FN-15 positive)
showed an indistinguishable morphology and spatial distribution;
since they are both murine anti-human monoclonal antibodies and
therefore cannot be used in combination, we have only followed the
former for the rest of the study.
Spatial relation of non-fibrillar FN to other structures (serum-
containing medium). We have first focused on MMP-2. This
protease has a certain degree of structural similarity to FN, with
three fibronectin-like domains allowing its binding to collagen/
gelatin27–29. MMP-2/FN colocalization has been occasionally
reported, e.g. in infected astrocytes30 and may arise from binding
to/competition for a common substrate; for example, when HDFs
are cultured on collagen IV, the colocalization of the substrate with
fibrillar FN31,32 is possibly coupled to that with MMP-2, which
eventually degrades FN31. This ternary collagen IV/MMP-2/FN
interplay may be influenced by the FN morphology: MMP-2 is
decreasingly activated with increasing binding of fibronectin by
integrins, which should cause FN increased fibrillization33.
The question is therefore whether non-fibrillar FN may be
associated to gelatinolytic sites, i.e. MMP-2 or MMP-9. We have
employed DQTM (dye-quenched) gelatin, which allows for a fluori-
metric detection of gelatinase activity. Incidentally, HDFs have
significant gelatinolytic activity in both protomyofibroblastic and
myofibroblastic state, as demonstrated also via zymography (see
Supplementary Information, Figure S4); this may correct earlier
reports that ascribed the gelatinase activity of fibrotic samples only
to macrophages34.
Figure 4 | Localization of fibronectin in HDFs cultured in 10% FBS. Top: In 10% FBS both ‘‘total’’ FN (imaged with the FN-15 antibody, A and B) and
ED-A FN (imaged with the IST-9 antibody, C and D) showed a strong epifluorescence emission, but a weak TIRF one. F-actin (green) showed a stronger
TIRF emission due to the localization of many stress fibres on the ventral surface of HDFs. Please note that FN appears to be present in a perinuclear region
in the two epifluorescence pictures; although frequent, this localization was not observed in all samples. Bottom: contact mode AFM pictures of fixed HDF
in PBS. The cell surfaces present ridges with heights at most of a couple of hundreds of nm, which correspond to the dorsal actin fibres (smaller for
transverse arcs); a similar picture is presented in Supplementary Information, Figure S3 (see Section 2 in Supplementary Information, Additional
Materials and Methods for experimental details). The picture in the right hand part shows the full contour of a peripheral part of an HDF body, as
highlighted by the black line); in areas where actin fibres are not present, the thickness decreases to less than 50 nm, which explains the bleeding of the
dorsal fluorescence on the ventral plane in Figure 5.
www.nature.com/scientificreports
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Irrespective of the presence of serum or TGF-b1, DQTM gelatin
showed a spotted, actin-avoiding fluorescence, with a pattern very
reminiscent of that of non-fibrillar FN (Figure 6).
Indeed, gelatinolytic sites showed an almost complete colocaliza-
tion with MMP-2 both before (Figure 7A, see also Supplementary
Information, Figure S7) and after TGF-b1 treatment (see Supple-
mentary Information, Figure S6A and Figure S8); in the absence of
gelatin, MMP-2 presented only a diffuse cytoplasmic staining pattern
(Figure 7B and Supplementary Information, Figure S6B), thus the pro-
tease apparently migrated to the cell surface in a substrate-dependent
fashion. It is worth pointing out that DQTM gelatin was incubated
overnight, but despite the rather long incubation we are confident that
MMP-2 and degraded DQTM gelatin did not undergo significant inter-
nalization: A) DQTM gelatin did not colocalize with late endosomes
(Figure 7C and Supplementary Information, Figure S6C); B) MMP-2
endocytosis is possibly associated to lipid rafts (the low density lipo-
protein receptor-related protein-1 (LRP-1) internalizes MMP-235–37
and is stabilized via cholesterol enrichment38), but no significant
colocalization between them and DQTM gelatin/MMP-2 was recorded
(Figure 7D and Supplementary Information, Figure S6D).
Therefore it seems safe to assume that it is still on the cell surface
that the gelatinolytic sites positively colocalized with non-fibrillar FN
(ED-A FN in Figure 8A) whereas actin/a-SMA negatively colocalized
with both (Figure 8B and C, see also Supplementary Information,
Figure S7 and S8). Please note that for ease of performance and higher
resolution, the colocalization was analyzed on epifluorescence rather
than confocal images, due to the thinness of the cell body (,200 nm,
similar to the voxel size).
Extending the study to other MMPs, we observed that MMP-3
mapped the F-actin localization (Figure 8D; see also Supplementary
Information, Figure S7 and S8) and avoided MMP-2/DQTM gelatin/
ED-A FN areas (Figure 9B and C). MMP-1 and MMP-14 showed no
preferential spatial association with either actin or FN (Figure 9A and
D; see also Supplementary Information, Figure S7 and S8).
A quantitative analysis confirmed the serum-induced colocaliza-
tion of DQTM gelatin and ED-A FN, and its mutual exclusion with
Figure 5 | Confocal microscopy of ED-A FN (red) imaged with the IST-9 antibody. The non-fibrillar form of FN appears to be present dorsally and
localized between neighboring actin fibres (green); within the resolution of the technique, there is no apparent difference in vertical position between
actin and FN. It should be noted that the low intensity ventral red fluorescence is actually due to dorsally localized components that cannot be completely
separated due to a cell thickness (,100 nm, see AFM pictures in Figure 4, bottom) of the same order of magnitude of a confocal voxel. On the contrary,
the fibrillar form recorded in serum-free medium was clearly positioned ventrally, in between cell body and substrate.
www.nature.com/scientificreports
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MMP-3 and actin (see Supplementary Information, Table S2 and
Figure S9). It is noteworthy that replacing 10% FBS with serum-free
medium the colocalization of ED-A FN and actin changed from
mutually exclusive to random (see also Figure 2), whereas DQTM
Gelatin and actin kept their mutually exclusive distribution.
Discussion
A comparison with recent literature makes it possible to draft some
tentative links:
Figure 6 | Localization of gelatinolytic sites (green fluorescence) and
actin (red fluorescence) for HDFs cultured under serum-free conditions
(top) or in 10% FBS (bottom) and with (right) or without (left) 10 ng/mL
TGF-b1. DQTM gelatin fluorescein groups are quenched in the
macromolecule prior to degradation due to its high degree
functionalization, whereas they fluoresce upon enzymatic cleavage with an
intensity proportional to the extent of degradation. The oval insets show
magnified portions of the pictures in inverted colours for an easier
appreciation of the localization of DQTM gelatin fluorescence
predominantly between actin fibres.
Figure 7 | Fluorescence microscopy images of HDFs exposed to DQTM
gelatin in 10% FBS without TGF-b1. In all images green fluorescence
corresponds to gelatin degradation. Red fluorescence corresponds to
MMP-2 (rabbit polyclonal antibody and anti-rabbit ChromeoTM) in (A)
and (B), to endolysosomal compartments (Lysotracker) in (C), to lipid
rafts (Cholera Toxin B) in (D). Please note that 10 ng/mL TGF-b1
provided indistinguishable results, see Supplementary Information,
Figure S6.
Figure 8 | Fluorescence images for HDFs cultured in 10% FBS without
TGF-b1. (A): ED-A FN (red) and degraded gelatin (green) showed an
almost perfect colocalization; please note, although in this part of the study
we have focused on ED-A FN, FN and ED-A FN share the same localization
pattern (Figure 2). (B): a-SMA was substantially absent without TGF-b1,
but in myofibroblasts it mapped the localization of F-actin and thus
showed a virtually complete exclusion with ED-A FN. (C): Evidence of
mutual exclusion between actin and DQTM gelatin, as shown also in
Figure 5. (D): MMP-3 (green) showed a predominantly fibrillar
distribution that colocalized with that of actin (red), although some
protease also accumulated in the perinuclear area. The separate green and
red channels for all pictures are presented in Supplementary Information,
Figure S7, right. Please note that 10 ng/mL TGF-b1 provided
indistinguishable results, see Supplementary Information, Figure S8.
Figure 9 | Fluorescence images for HDFs exposed to DQTM gelatin in 10%
FBS without TGF-b1. In all images the green fluorescence corresponds to
gelatin degradation. The red fluorescence corresponds to MMP-1 (A),
MMP-3 (B), MMP-2 (C) and MMP-14 (D); for the latter, the fluorescence
pattern would suggest an intracellular/perinuclear localization (shape
reminiscent of the Golgi). The separate green and red channels for all
pictures are presented in Supplementary Information, Figure S7, left.
Please note that 10 ng/mL TGF-b1 provided indistinguishable results, see
Supplementary Information, Figure S8.
www.nature.com/scientificreports
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A) Positive colocalization between non-fibrillar FN and MMP-2
and mutual exclusion with actin. First, recent evidence supports
this finding; for example, Jacob et al. showed positive and negative
colocalization respectively for gelatin/fibronectin and for MMP-2/
actin in MDA-MB-231 cells cultured on a gelatin-coated substrate39.
Further, MDA-MB-231 invadopodia showed gelatinolytic sites with
a pattern analogous to our observations, which were surrounded by
but did not overlap with F-actin40.
Second, in a serum-containing medium the positive MMP-2/FN
colocalization may be the result of a functional link. ED-A FN was
predominantly non-fibrillar irrespective of the presence of gelatin.
When added, the latter adopted the ED-A FN morphology and
MMP-2 follows suit, possibly suggesting that gelatin/FN binding
precedes or even causes the MMP-2 surface migration; this may
explain the significantly reduced MMP-2 expression in ED-A FN
knockout mice41. In the absence of serum, the fibrillar FN no longer
showed a preferential colocalization with gelatin and therefore dif-
ferences in FN-based signalling are possible.
Third, also the actin/MMP-2 negative colocalization may stem
from a functional link, albeit unknown. Some literature reports point
in this direction; for example, MMP-2 activation increased upon
treatment with the actin-disrupting cytochalasin D in human tra-
becular meshwork cells42, in human palmar fascia fibroblasts and in
human foetal lung fibroblasts43, whereas the disruption of microtu-
bules (via nocodazole) did not have an effect on the protease. In a
reciprocal fashion Jin et al. showed that Akt-mediated activation of
MMP-2 in chick wing buds mesenchymal cells resulted in actin
cytoskeleton reorganization44.
B) Positive colocalization between actin and MMP-3. To the best of
our knowledge, a topological association between MMP-3 and cytos-
keletal elements has never been reported, but there are evidences
of a close functional relationship: for example, MMP-3-deficient
fibroblasts showed an impaired contraction in vitro45, whereas
MMP-3 knockout mice presented an impaired early wound con-
traction due to inadequate actin organisation in fibroblasts46.
Additionally, it has been shown that in the contraction of collagen
gels by osteoblasts MMP-3 (and MMP-1) and a2 integrins follow a
similar path of expression47.
C) No difference following TGF-b1 treatment. It is noteworthy that
two HDF phenotypes were used, i.e. protomyofibroblastic (no TGF-
b1, but yet ED-A FN expression) and myofibroblastic (10 ng/mL
TGF-b1, with expression of both ED-A FN and a-SMA); however,
this did not affect the distribution and morphology of any of these
structural or functional elements (compare Figure S7 and S8 in
Supplementary Information).
Conclusion
A serum-free (myo)fibroblast model is definitely artificial, but how
appropriate and reproducible is one with serum? Our results point
out that it may be equally artificial and possibly less reproducible. In
short, the two main caveats are a) the presence of variable amounts of
TGF-b1 (and possibly other cytokines), which leads to variable levels
of overexpression of myofibroblast markers, and b) the reduced level
of fibrillization of endogenous FN, possibly because of the presence
of other serum-borne factors that compete for integrin binding,
which may also have downstream effects in terms of cellular
signaling.
Incidentally, proteolytic sites and structural elements appeared to
have identical topological links in protomyofibroblasts and in myo-
fibroblasts; this would indicate that, despite their different contract-
ility, the two cell types may have a similar mechano-transducive
machinery controlling their interaction with the extracellular
matrix.
Methods
Chemical reagents and general cell culture. Primary human dermal fibroblasts
(HDFs) (C-013-5C) were purchased from Cascade Biologics/Invitrogen (Paisley, UK)
and used within passage 3–6 from reception. HDF were cultured using high glucose
Dulbecco’s Modified Eagle Medium (DMEM, D6546, Sigma-Aldrich) supplemented
with 10% v/v foetal bovine serum (FBS, Invitrogen), 1% v/v penicillin/streptomycin
solution (Sigma-Aldrich), 1% v/v L-glutamine (Invitrogen) and incubated under
sterile conditions at 37uC/5% CO2. For all experiments, cells were seeded in the
appropriate culture vessel and allowed to attach for 24 hours in presence of 10%
serum. Subsequently, they were washed 3 times with warm serum-free medium
(SFM), and treated for 48 hours with TGF-b1 (human recombinant, Abcam, UK) or
bovine fibronectin (F1141, Sigma) in SFM or 10% serum, according to the desired
experimental conditions. Please note that the use of human TGF-b1 in murine
fibroblast cell lines is a common practice48–51, due also to its close homology to the
murine growth factor (identical 390 aa length and 89.7% identity). For fluorimetric
quantification (e.g. DAPI or DQTM gelatin) cells were grown on black 96 well plates
(Greiner Bio-One), and fluorescence was measured with a Safire microplate reader
(Tecan, Männedorf, CH). Excitation/emission maxima for DAPI and DQTM gelatin
were 358/461 nm and 485/520 nm, respectively.
Experimental descriptions for RNA analysis and qRT/PCR, Atomic Force
Microscopy (AFM), gel zymography and quantitative colocalization analysis. See
Supplementary Information, section 2 (Comparison of the effects of TGFb1 exposure
in murine cell lines and in HDFs), 3 (AFM on cells), 4 (Gelatin degradation) and 5
(Colocalization analysis).
Enzyme-linked immunosorbent assay (ELISA). The TGF-b1 content of sera
sourced from different manufacturers was assayed using the NovexH TGF-b1
Multispecies ELISA Kit (Life Technologies, Paisley, UK) according to the
manufacturer’s instructions. The enzyme-mediated transformation of the
chromogen in a coloured product was assayed measuring the 450 nm absorbance of
each well using a Synergy 2 Biotek microplate reader. A calibration curve was built via
serial dilutions of a supplied TGF-b1 standard. All absorbance measurements fell
within the linear portion of the standard curve, thus ensuring the accuracy of the
extrapolation.
Immunocytochemistry and fluorescence microscopy. Cells were seeded at a density
of 5 3 103 cells/mL in slide flasks (Nunc-Fisher Scientific, Loughborough, UK) and
were subjected to overnight incubation with 100 mg/mL of highly quenched
fluorescein-labeled gelatin (DQTM Gelatin D-12054, Molecular ProbesH, Eugene,
Oregon). The cells were then washed with PBS and fixed with 4% v/v
paraformaldehyde/PBS for 30 minutes. For immunocytochemistry and phalloidin
staining, permeabilization was performed using 0.25% v/v Triton X-100/PBS (Sigma-
Aldrich) for 30 minutes followed by blocking using 5% v/v goat serum/PBS (Sigma-
Aldrich) for 1 hour. Incubation of the following primary antibodies (all purchased
from Abcam, Cambridge, UK) was performed at room temperature for 1 hour in 5%
v/v goat serum/PBS: MMP-1 (rabbit polyclonal, 15200), MMP-2 (rabbit polyclonal,
15200), MMP-3 (rabbit polyclonal, 15200), MMP-14 (rabbit polyclonal, 15200),
vinculin (SPM227 mouse monoclonal, 15200), a-SMA (rabbit polyclonal, 15200),
ED-A FN (IST-9 mouse monoclonal, 15200), total cellular fibronectin (FN-15, mouse
monoclonal, 15200) and bovine fibronectin (AB2047, rabbit polyclonal, 15200). The
cells were rinsed in PBS before incubation with the corresponding secondary
antibodies: anti-rabbit ChromeoTM 488-conjugated secondary antibody (151000,
goat polyclonal), anti-mouse ChromeoTM 546-conjugated secondary antibody
(151000, goat polyclonal), anti-mouse ChromeoTM 488-conjugated secondary
antibody (151000, goat polyclonal) in PBS for 1 hour. F-actin fibres were stained
using 1540 Alexa FluorH 594-/488-conjugated phalloidin (Invitrogen) in 1% w/v
bovine serum albumin/PBS for 1 hour. Late endosome/lysosome staining was
performed by using 1 mM LysoTrackerH Red DND-99 (Molecular Probes) for 1 hour,
according to the manufacturer’s instructions. Lipid rafts were stained with
25 mg/mL Alexa FluorH 594-conjugated Cholera Toxin-B (CT-B, Invitrogen)
for 1 hour in 5% w/v bovine serum albumin (BSA, Sigma-Aldrich). Cells
were then mounted and counterstained using VECTASHIELDH mounting medium
with 49,6-diamidino-2-phenyl-indole (DAPI) (Vector Laboratories, Peterborough,
UK).
Widefield images with 16-bit resolution and pixel size of 0.44 mm were obtained
using a Olympus BX51 upright widefield microscope with a 60x/0.65–1.25NA Plan
Fln oil immersion objective (Tokyo, Japan) and captured using a Coolsnap ES camera
(Photometrics, Tucson, Arizona, USA) through MetaVueTM Research Imaging
Software (Molecular Devices, Sunnyvale, California). Specific band pass filter sets for
DAPI (excitation: BP350/50 nm; emission: BP460/50 nm), fluorescein isothiocya-
nate (FITC; excitation: BP480/40 nm; emission: BP535/50 nm), and Texas Red
(excitation: BP560/55 nm; emission: BP645/75 nm) were used to prevent bleed-
through from one channel to the next. For Total Internal Reflection Fluorescence
(TIRF) experiments, images were collected on a TE2000 microscope (Nikon),
equipped with a perfect focus system to eliminate focus drift, using a 100x/1.49 Apo
TIRF objective. The 488 nm laser line was manually adjusted until TIRF was achieved
and the images were then collected through the Elements software (Nikon) using a
Cascade 512B EM CCD camera (Photometrics).
Confocal images were collected on a Leica TCS SP5 AOBS inverted confocal using a
63x/0.60–1.40/HCX PL Apo objective. The confocal settings were as follows: pinhole
50 mm, scan speed 400 Hz unidirectional, frame average 32. Images were collected
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sequentially using the following detection mirror settings: 405 nm (15%), 488 nm
(50%) and 561 nm (30%) laser lines respectively. When acquiring 3D optical stacks
the confocal software was used to determine the optimal number of Z sections.
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